Biomarkers And Immuno-Oncology: Identifying New Opportunities For Precision Medicine

Predictive and pharmacodynamic biomarkers are a critical component of today’s progress in immuno-oncology (IO) drug development. While predictive biomarkers can accelerate development by identifying the right group of patients to target and ensuring safety and efficacy of the compound, there are inherent challenges in finding and validating biomarkers that will end as companion diagnostics. Pharmacodynamic markers are very useful in early stages of development to help identify the true mechanism of action in humans. The straightforward approach to find and apply these types of markers is more complex in IO.

Join us in this informative webinar to hear about the latest issues in biomarker development and explore the critical junction between pharmaceutical companies, companion diagnostic manufacturers and CROs to enable an effective co-development process.